Antidepressant drug effects and depression severity: a patient-level meta-analysis.
暂无分享,去创建一个
[1] N. Nicolson,et al. Reduced Stress-Sensitivity or Increased Reward Experience: The Psychological Mechanism of Response to Antidepressant Medication , 2009, Neuropsychopharmacology.
[2] S. Montgomery,et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial , 2008, International clinical psychopharmacology.
[3] S. Montgomery,et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder , 2008, International clinical psychopharmacology.
[4] M. Liebowitz,et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder* , 2008 .
[5] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[6] R. Rosenthal,et al. Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.
[7] M. Liebowitz,et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. , 2007, The Journal of clinical psychiatry.
[8] B. Pitrosky,et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder , 2007, International clinical psychopharmacology.
[9] 杉浦 義典. 読む 海外文献紹介(第37回)Dimidjian S et al "Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression"[成人の大うつ病に対する行動活性化,認知療法,抗うつ剤のランダム化比較試験] , 2007 .
[10] N. DeMartinis,et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. , 2007, The Journal of clinical psychiatry.
[11] K. Rickels,et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. , 2006, The Journal of clinical psychiatry.
[12] David C. Atkins,et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. , 2006, Journal of consulting and clinical psychology.
[13] David J. Kupfer,et al. Size of Treatment Effects and Their Importance to Clinical Research and Practice , 2006, Biological Psychiatry.
[14] M. Gastpar,et al. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. , 2006, Pharmacopsychiatry.
[15] R. DeRubeis,et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. , 2005, Archives of general psychiatry.
[16] M. Posternak,et al. Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression? , 2005, Journal of clinical psychopharmacology.
[17] Nice. Depression: management of depression in primary and secondary care , 2005 .
[18] R. Bagby,et al. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? , 2004, The American journal of psychiatry.
[19] R. Lipman,et al. Drug effects and initial severity of symptomatology , 1965, Psychopharmacologia.
[20] Kathryn A Sexton,et al. Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation , 2004, Depression and anxiety.
[21] M. Berner. [The treatment of major depression]. , 2004, Pharmazie in unserer Zeit.
[22] M. Posternak,et al. Symptom Severity and Exclusion From Antidepressant Efficacy Trials , 2002, Journal of clinical psychopharmacology.
[23] John C. Markowitz,et al. Treatment and Prevention of Depression , 2002, Psychological science in the public interest : a journal of the American Psychological Society.
[24] Robyn M Leventhal,et al. Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database , 2002, Journal of clinical psychopharmacology.
[25] M. Hegel,et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. , 2001, The Journal of family practice.
[26] D. Dunner. Acute and maintenance treatment of chronic depression. , 2001, The Journal of clinical psychiatry.
[27] Michael B. First,et al. Handbook of Psychiatric Measures , 2000 .
[28] M. Demitrack,et al. The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period , 2000, Biometrics.
[29] R. Kohnen,et al. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. , 1999, BMJ.
[30] S. Wessely,et al. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis , 1999, Psychological Medicine.
[31] M. Trivedi,et al. Evidence Report: Treatment of Depression - Newer Pharmacotherapies , 1999 .
[32] L. Stewart,et al. Re: "Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies". , 1998, American journal of epidemiology.
[33] M. Trivedi,et al. Treatment of depression--newer pharmacotherapies. , 1998, Psychopharmacology bulletin.
[34] I Olkin,et al. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. , 1997, American journal of epidemiology.
[35] Feiger Ad. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. , 1996, Psychopharmacology bulletin.
[36] J. Ieni,et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. , 1996, The Journal of clinical psychiatry.
[37] A. Feiger. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. , 1996, Psychopharmacology bulletin.
[38] D. Baldwin,et al. Dysthymia: Options in Pharmacotherapy , 1995 .
[39] L. Mynors-Wallis,et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care , 1995, BMJ.
[40] M. Trivedi,et al. Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications? , 1994, Neuropsychopharmacology.
[41] T. Silverstone. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder , 1994, International clinical psychopharmacology.
[42] S. Dager,et al. Chronicity of depressive episode in relation to antidepressant-placebo response. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[43] A. Nardi,et al. Moclobemide, imipramine and placebo in the treatment of major depression , 1990, Acta psychiatrica Scandinavica. Supplementum.
[44] J. Guelfi,et al. Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression , 1990, Acta psychiatrica Scandinavica. Supplementum.
[45] D. Robinson,et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. , 1990, Psychopharmacology bulletin.
[46] S D Imber,et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. , 1989, Archives of general psychiatry.
[47] M. Versiani,et al. A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes , 1989, British Journal of Psychiatry.
[48] E. Paykel,et al. Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. , 1988, The Journal of the Royal College of General Practitioners.
[49] E. Giller,et al. Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. , 1984, The Journal of clinical psychiatry.
[50] Lofepramine and imipramine in unipolar depressed outpatients , 1982 .
[51] K. Rickels,et al. Trazodone in depressed outpatients. , 1982, The American journal of psychiatry.
[52] K. Rickels,et al. Lofepramine and imipramine in unipolar depressed outpatients. A placebo controlled study. , 1982, Acta psychiatrica Scandinavica.
[53] L. Benjamin. Statistical Treatment of the Law of Initial Values (LIV) in Autonomic Research: A Review and Recommendation , 1963, Psychosomatic medicine.
[54] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.